Rhodococcus equi hyperimmune plasma decreases pneumonia severity after a randomised experimental challenge of neonatal foals.

Summary

# Editorial summary: Rhodococcus equi hyperimmune plasma and neonatal pneumonia Rhodococcal pneumonia remains a significant challenge in neonatal foal populations, particularly because no licensed vaccine exists against *Rhodococcus equi*, making passive immunisation through hyperimmune plasma (HIP) a pragmatic intervention despite ongoing debate about its clinical value. Sanz and colleagues conducted a randomised experimental challenge study in which neonatal foals received either *R. equi*-specific hyperimmune plasma or control plasma, followed by controlled bacterial challenge to assess whether HIP could mitigate disease severity. Foals treated with hyperimmune plasma developed significantly less severe pneumonia compared to controls, though the plasma did not prevent infection entirely, suggesting a protective rather than preventative mechanism. These findings provide evidence supporting the clinical use of *R. equi*-specific HIP as part of a management strategy for at-risk neonates, particularly in endemic settings or high-risk breeding operations where colostral antibody concentrations may be inadequate. Given that HIP cannot guarantee protection and infection rates remain variable, continued emphasis on optimising colostral transfer, environmental management and early clinical surveillance remains essential alongside any decision to use hyperimmune plasma therapeutically.

Read the full abstract on PubMed

Key Findings

• •Hyperimmune plasma treatment decreased pneumonia severity in experimentally challenged neonatal foals
• •R equi-specific hyperimmune plasma demonstrated protective efficacy against clinical rhodococcal infection
• •Results support the use of commercially available HIP as a preventive intervention in at-risk neonatal foals

Conditions Studied

Tags